Liver transplant complications in hepatitis C infected recipients: recurrence versus rejection

Area of Science:

• Hepatology and Transplant Immunology
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Liver transplantation (LT) outcomes have improved, yet complications like HCV recurrence (HCV-rec) and acute cellular rejection (ACR) persist.
• Differentiating between HCV-rec and ACR post-LT is challenging due to overlapping clinical and histopathological features.
• Accurate diagnostic tools are essential for timely and effective management of these post-transplant complications.

Discussion:

• Recent technological advancements are driving biomarker discovery for complex diseases.
• Identifying specific biomarkers to differentiate ACR from HCV-rec is a critical unmet need in the transplant community.
• This editorial reviews emerging biomarkers across genomics, proteomics, and immunohistochemistry.

Key Insights:

• Genomic, proteomic, and immunohistochemical approaches show promise for differentiating post-LT complications.
• Biomarker panels may offer improved diagnostic accuracy over single markers.
• Non-invasive biomarker tests could reduce the need for invasive biopsies.

Outlook:

• Further validation of identified biomarkers in larger patient cohorts is necessary.
• Development of clinical assays for routine use in post-LT patient monitoring.
• Personalized treatment strategies based on precise diagnosis of ACR versus HCV-rec.